Hydroxychloroquine, a promising choice for coronary artery disease?

Medical Hypotheses

Volumn 93, Issue , 2016, Pages 5-7

  Sun, Lizhe ^a   Liu, Mengping ^a   Li, Ruifeng ^a   Zhao, Qiang ^a   Liu, Junhui ^a   Yang, Yanjie ^a   Zhang, Lisha ^a   Bai, Xiaofang ^a   Wei, Yuanyuan ^a   Ma, Qiangqiang ^a   Zhou, Juan ^a   Yuan, Zuyi ^a   Wu, Yue ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Atherosclerosis; Coronary artery disease; Hydroxychloroquine

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; ANTIMALARIAL AGENT; ANTITHROMBOCYTIC AGENT; LIPID;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; CORONARY ARTERY SURGERY; DIABETES MELLITUS; DRUG SAFETY; DRUG TOLERABILITY; GLYCEMIC CONTROL; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN RESISTANCE; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LONG TERM CARE; LUPUS ERYTHEMATOSUS; NONHUMAN; PATHOGENESIS; RHEUMATOID ARTHRITIS; SEDENTARY LIFESTYLE; SMOKING; THROMBOCYTE AGGREGATION INHIBITION; ANIMAL; ARTHRITIS, RHEUMATOID; CHEMISTRY; DISEASE MODEL; INFLAMMATION; RISK FACTOR; THEORETICAL MODEL;

ANIMALS; ANTIMALARIALS; ARTHRITIS, RHEUMATOID; CORONARY ARTERY DISEASE; DISEASE MODELS, ANIMAL; HUMANS; HYDROXYCHLOROQUINE; INFLAMMATION; INSULIN RESISTANCE; LIPIDS; MODELS, THEORETICAL; PLATELET AGGREGATION INHIBITORS; RISK FACTORS;

EID: 84966412963     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2016.04.045     Document Type: Article

References (23)

1. Chen W., Gao R., Liu L., et al. Report for Chinese cardiovascular disease in 2014. Chin Circul J 2015, 07:617-622.
2. Zhao Z., Wu Y., Cheng M., et al. Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome. Atherosclerosis 2011, 217(2):518-524.
3. Randel A. AHA/ACC/ASH release guideline on the treatment of hypertension and CAD. Am Fam Physician 2015, 92(11):1023-1030.
4. Al-Bari M.A. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother 2015, 70(6):1608-1621.
5. Titus E.O. Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine. Ther Drug Monit 1989, 11(4):369-379.
6. Raghoebar M., Peeters P.A., van den Berg W.B., van Ginneken C.A. Mechanisms of cell association of chloroquine to leucocytes. J Pharmacol Exp Ther 1986, 238(1):302-306.
7. Jancinova V., Nosal R., Petrikova M. On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb Res 1994, 74(5):495-504.
8. Achuthan S., Ahluwalia J., Shafiq N., et al. Hydroxychloroquine's efficacy as an antiplatelet agent study in healthy volunteers: a proof of concept study. J Cardiovasc Pharmacol Ther 2015, 20(2):174-180.
9. Jung H., Bobba R., Su J., et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010, 62(3):863-868.
10. Desai R.J., Eddings W., Liao K.P., Solomon D.H., Kim S.C. Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study. Arthritis Care Res (Hoboken) 2015, 67(4):457-466.
11. Rho Y.H., Oeser A., Chung C.P., Milne G.L., Stein C.M. Drugs used in the treatment of rheumatoid arthritis: relationship between current use and cardiovascular risk factors. Arch Drug Inf 2009, 2(2):34-40.
12. Solomon D.H., Garg R., Lu B., et al. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. Arthritis Care Res (Hoboken) 2014, 66(8):1246-1251.
13. Kim W.U., Seo Y.I., Park S.H., et al. Treatment with cyclosporin switching to hydroxychloroquine in patients with rheumatoid arthritis. Ann Rheum Dis 2001, 60(5):514-517.
14. Chen Y.M., Lin C.H., Lan T.H., et al. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. Rheumatology (Oxford) 2015, 54(7):1244-1249.
15. Mercer E., Rekedal L., Garg R., Lu B., Massarotti E.M., Solomon D.H. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Res Ther 2012, 14(3):R135.
16. Quatraro A., Consoli G., Magno M., et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug?. Ann Intern Med 1990, 112(9):678-681.
17. f: novel electrophysiological insights and therapeutic potential. Heart Rhythm 2015, 12(10):2186-2194.
18. Meng J., Lu Y., Dong X., Liu H. Long-term effects of hydroxychloroquine on metabolism of serum lipids and left ventricular structure and function in patients of systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi 2014, 94(13):965-968.
19. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 2010, 10(1):36-46.
20. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473(7347):317-325.
21. Chung C.P., Oeser A., Raggi P., et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005, 52(10):3045-3053.
22. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008, 121(10 Suppl. 1):S21-S31.
23. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005, 35(1):8-17.